Ovarian hilus cell (Leydig cell) hyperplasia associated with masculinization. 1953

I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D006984 Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA). Hypertrophies
D007985 Leydig Cells Steroid-producing cells in the interstitial tissue of the TESTIS. They are under the regulation of PITUITARY HORMONES; LUTEINIZING HORMONE; or interstitial cell-stimulating hormone. TESTOSTERONE is the major androgen (ANDROGENS) produced. Interstitial Cells, Testicular,Leydig Cell,Testicular Interstitial Cell,Testicular Interstitial Cells,Cell, Leydig,Cell, Testicular Interstitial,Cells, Leydig,Cells, Testicular Interstitial,Interstitial Cell, Testicular
D008297 Male Males
D010049 Ovarian Diseases Pathological processes of the OVARY. Disease, Ovarian,Diseases, Ovarian,Ovarian Disease
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D004194 Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown. Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014770 Virilism Development of male secondary SEX CHARACTERISTICS in the FEMALE. It is due to the effects of androgenic metabolites of precursors from endogenous or exogenous sources, such as ADRENAL GLANDS or therapeutic drugs. Androgenization,Virilization

Related Publications

I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
January 2009, European journal of gynaecological oncology,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
July 1960, Revista de la Asociacion Medica Argentina,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
April 1984, Mayo Clinic proceedings,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
December 1962, Proceedings of the Royal Society of Medicine,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
April 1965, The Journal of obstetrics and gynaecology of the British Commonwealth,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
January 1956, Cancer,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
February 1958, Orvosi hetilap,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
October 1964, Obstetrics and gynecology,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
January 1956, Quarterly bulletin. Northwestern University (Evanston, Ill.). Medical School,
I TALIAFERRO, and E J WELLS, and S KAY, and R H HOGE
November 1981, Orvosi hetilap,
Copied contents to your clipboard!